Therapeutic Effects of Fibrates in Postprandial Lipemia

No abstract is available for this paper.

• Publication year

  2008

• Venue

  American Journal of Cardiovascular Drugs

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.2165/00129784-200808040-00004PMID 18690758
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National

  2009cited by this paper
• Alimentary lipemia enhances procoagulatory effects of inflammation in patients with a history of acute myocardial infarction complicated by ventricular fibrillation.

  2008cited by this paper
• Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women.

  2007cited by this paper
• Fenofibrate Effect on Triglyceride and Postprandial Response of Apolipoprotein A5 Variants: The GOLDN Study

  2007cited by this paper
• Expert commentary: the safety of fibrates in lipid-lowering therapy.

  2007cited by this paper
• Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women.

  2007cited by this paper
• Are the lipid-modifying effects of fibrates mediated by alterations in plasma lipid transfer activity?

  2006cited by this paper
• PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases.

  2006cited by this paper
• Relationships between changes in plasma lipid transfer proteins and apolipoprotein B-100 kinetics during fenofibrate treatment in the metabolic syndrome.

  2006cited by this paper
• Bezafibrate may attenuate biliary damage associated with chronic liver diseases accompanied by high serum biliary enzyme levels

  2006cited by this paper
• Postprandial lipaemia in menopausal women with metabolic syndrome.

  2006cited by this paper
• Fenofibrate can increase serum creatinine levels in renal insufficiency.

  2006cited by this paper
• A case of rhabdomyolysis induced acute renal failure secondary to statin-fibrate-derivative combination and occult hypothyroidism.

  2005cited by this paper
• Bezafibrates Cause Moderate, Reversible Impairment in Renal Function in Patients without Prior Renal Disease

  2005cited by this paper
• Efficacy and safety profile of fenofibrate-coated microgranules 130 mg, with and without food, in patients with hypertriglyceridemia and the metabolic syndrome: an 8-week, randomized, double-blind, placebo-controlled study.

  2005cited by this paper
• Acute myopathy in a type 2 diabetic patient on combination therapy with metformin, fenofibrate and rosiglitazone

  2005cited by this paper
• Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.

  2005cited by this paper
• Clinical relevance of postprandial lipaemia.

  2005cited by this paper
• Protective effect of coenzyme Q10 in simvastatin and gemfibrozil induced rhabdomyolysis in rats.

  2005cited by this paper
• Pleiotropic effects of fibrates

  2005cited by this paper
• The effect of fibrates and other lipid-lowering drugs on plasma homocysteine levels.

  2004cited by this paper
• Risk of adverse events with fibrates.

  2004cited by this paper
• Effect of fibrates on postprandial remnant-like particles in patients with combined hyperlipidemia.

  2004cited by this paper
• Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

  2004cited by this paper
• Fenofibrate for patients with asymptomatic primary biliary cirrhosis.

  2004cited by this paper
• Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects

  2004cited by this paper
• Effect of gemfibrozil on change in renal function in men with moderate chronic renal insufficiency and coronary disease.

  2004cited by this paper
• The VLDL receptor plays a major role in chylomicron metabolism by enhancing LPL-mediated triglyceride hydrolysis Published, JLR Papers in Press, May 16, 2004. DOI 10.1194/jlr.M400009-JLR200

  2004cited by this paper
• Fibrate treatment and prevalence risk of mild hyperhomocysteinaemia in clinical coronary heart disease patients

  2004cited by this paper
• Comparative Effects of Atorvastatin, Simvastatin, and Fenofibrate on Serum Homocysteine Levels in Patients with Primary Hyperlipidemia

  2003cited by this paper
• Micronized fenofibrate normalizes the enhanced lipidemic response to a fat load in patients with type 2 diabetes and optimal glucose control.

  2003cited by this paper
• Effect of baseline levels on response of high-density lipoprotein cholesterol to hypolipidemic treatment.

  2003cited by this paper
• Effects of fenofibrate on endothelial function and cell adhesion molecules during post‐prandial lipemia in hypertriglyceridemia

  2003cited by this paper
• Chylomicron remnants of various sizes are lowered more effectively by fenofibrate than by atorvastatin in patients with combined hyperlipidemia.

  2003cited by this paper
• Effects of Fibrates on Serum Metabolic Parameters

  2002cited by this paper
• Fenofibrate treatment in patients with primary biliary cirrhosis

  2002cited by this paper
• Postprandial lipemia--effect of lipid-lowering drugs.

  2002cited by this paper
• The effects of gemfibrozil on hyperlipidemia in children with persistent nephrotic syndrome.

  2002cited by this paper
• Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

  2002cited by this paper
• Effect of fenofibrate on brachial artery flow-mediated dilatation in type 2 diabetes mellitus.

  2002cited by this paper
• Effect of Ciprofibrate on Lipoproteins, Fibrinogen, Renal Function, and Hepatic Enzymes

  2002cited by this paper
• Postprandial remnant-like lipoproteins in hypertriglyceridemia.

  2001cited by this paper
• Negative Regulation of Human Fibrinogen Gene Expression by Peroxisome Proliferator-activated Receptor α Agonists via Inhibition of CCAAT Box/Enhancer-binding Protein β*

  2001cited by this paper
• Dietary cholesterol is secreted in intestinally derived chylomicrons during several subsequent postprandial phases in healthy humans.

  2001cited by this paper
• Effects of fenofibrate and gemfibrozil on plasma homocysteine.

  2001cited by this paper
• Fibrates Suppress Bile Acid Synthesis via Peroxisome Proliferator–Activated Receptor-&agr;–Mediated Downregulation of Cholesterol 7&agr;-Hydroxylase and Sterol 27-Hydroxylase Expression

  2001cited by this paper
• Fenofibrate‐Induced Elevation in Serum Creatinine

  2001cited by this paper
• Effect of statin versus fibrate on postprandial endothelial dysfunction: role of remnant-like particles.

  2001cited by this paper
• Increased plasma apoA-IV level is a marker of abnormal postprandial lipemia: a study in normoponderal and obese subjects.

  2001cited by this paper
• Inhibitory action of gemfibrozil on cholesterol absorption in rat intestine.

  2001cited by this paper
• Fenofibrate raises plasma homocysteine levels in the fasted and fed states.

  2001cited by this paper
• The biochemistry of hypo- and hyperlipidemic fatty acid derivatives: metabolism and metabolic effects.

  2001cited by this paper
• The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood.

  2001cited by this paper
• PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway

  2001cited by this paper
• Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study.

  2001cited by this paper
• Negative regulation of human fibrinogen gene expression by peroxisome proliferator-activated receptor alpha agonists via inhibition of CCAAT box/enhancer-binding protein beta.

  2001cited by this paper
• Recent findings in the study of postprandial lipemia

  2001cited by this paper
• PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway.

  2000cited by this paper
• Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus.

  2000cited by this paper
• Regulation of Lipid and Lipoprotein Metabolism by PPAR Activators

  2000cited by this paper
• Remnant-like particle cholesterol and triglyceride levels of hypertriglyceridemic patients in the fed and fasted state.

  2000cited by this paper
• Postprandial concentrations and distribution of apo C-III in type 2 diabetic patients. Effect Of bezafibrate treatment.

  2000cited by this paper
• CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors.

  2000cited by this paper
• Postprandial reverse cholesterol transport in type 2 diabetic patients: effect of a lipid lowering treatment.

  2000cited by this paper
• Effect of micronized fenofibrate on plasma lipoprotein levels and hemostatic parameters of hypertriglyceridemic patients with low levels of high-density lipoprotein cholesterol in the fed and fasted state.

  2000cited by this paper
• Bezafibrate in the treatment of primary biliary cirrhosis: comparison with ursodeoxycholic acid

  2000cited by this paper
• Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease.

  2000cited by this paper
• Ciprofibrate effects on carbohydrate and lipid metabolism in type 2 diabetes mellitus subjects.

  2000cited by this paper
• Peroxisome proliterator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis

  1999cited by this paper
• Ratio of remnant-like particle-cholesterol to serum total triglycerides is an effective alternative to ultracentrifugal and electrophoretic methods in the diagnosis of familial type III hyperlipoproteinemia.

  1999cited by this paper
• Characterization of remnant-like particles isolated by immunoaffinity gel from the plasma of type III and type IV hyperlipoproteinemic patients.

  1999cited by this paper
• Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis.

  1999cited by this paper
• Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.

  1999cited by this paper
• Detection, quantification, and characterization of potentially atherogenic triglyceride-rich remnant lipoproteins.

  1999cited by this paper
• Membrane active lipids in remnant lipoproteins cause impairment of endothelium-dependent vasorelaxation.

  1999cited by this paper
• Post-prandial effects of gemfibrozil vs simvastatin in hypercholesterolemic subjects with borderline hypertriglyceridemia.

  1999cited by this paper
• Cardiovascular Outcomes in Type 2 Diabetes: A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study

  1998cited by this paper
• Magnitude of alimentary lipemia is related to intima-media thickness of the common carotid artery in middle-aged men.

  1998cited by this paper
• Postprandial studies on dietary cholesterol in human subjects using stable isotopes and gas chromatography-mass spectrometry analysis.

  1998cited by this paper
• Effect of the fat composition of a single meal on the composition and cytotoxic potencies of lipolytically-releasable free fatty acids in postprandial plasma.

  1998cited by this paper
• Plasma remnant-like particle lipid and apolipoprotein levels in normolipidemic and hyperlipidemic subjects.

  1998cited by this paper
• Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis.

  1998cited by this paper
• Mechanism of action of fibrates on lipid and lipoprotein metabolism.

  1998cited by this paper
• Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT).

  1998cited by this paper
• Impaired endothelium-dependent acetylcholine-induced coronary artery relaxation in patients with high serum remnant lipoprotein particles.

  1998cited by this paper
• Role of apolipoprotein CIII in triglyceride-rich lipoprotein metabolism.

  1998cited by this paper
• Method for simultaneous measurements of traces of heptadeuterated cholesterol and cholesterol by gas chromatography-mass spectrometry: application in humans.

  1998cited by this paper
• Effects of fenofibrate on hyperlipidemia and postprandial triglyceride metabolism in human apolipoprotein C1 transgenic mice.

  1998cited by this paper
• Fenofibrate modifies transaminase gene expression via a peroxisome proliferator activated receptor alpha-dependent pathway.

  1998cited by this paper
• Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators.

  1997cited by this paper
• Hepatic uptake of chylomicron remnants.

  1997cited by this paper
• Postprandial hemorrheology and apolipoprotein B metabolism in patients with familial hypertriglyceridemia.

  1997cited by this paper
• Post‐prandial metabolism of triglyceride‐rich lipoproteins in non‐insulin‐dependent diabetic patients before and after bezafibrate treatment

  1997cited by this paper
• Coordinate Regulation of the Expression of the Fatty Acid Transport Protein and Acyl-CoA Synthetase Genes by PPARα and PPARγ Activators*

  1997cited by this paper
• Regulation of Bile Acid Biosynthesis

  1997cited by this paper
• Fibrates induce mdr2 gene expression and biliary phospholipid secretion in the mouse.

  1996cited by this paper
• Secondary preventive potential of lipid-lowering drugs. The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT).

  1996cited by this paper
• Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice.

  1996cited by this paper
• VLDL receptor mediates the uptake of human chylomicron remnants in vitro.

  1996cited by this paper
• The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation.

  1996cited by this paper

• Plasma reduction of apolipoprotein C-III with olezarsen leads to significant reductions in postprandial triglyceride levels: Results from a randomized trial.

  2025cites this paper
• Multi-Omics Identified THDCA as a Key Contributor to Hyperlipidemia and as a Potential Therapeutic Agent

  2023cites this paper
• Hypertriglyceridemia and Atherosclerotic Carotid Artery Stenosis

  2022cites this paper
• Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Narrative Review

  2019cites this paper
• Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Main Text

  2019cites this paper
• 16 Hypertriglyceride Induced Acute Pancreatitis

  2017cites this paper
• Postprandial dysmetabolism: Too early or too late?

  2016cites this paper
• Nonglycemic targets in diabetes.

  2015cites this paper
• Contemporary and Novel Therapeutic Options for Hypertriglyceridemia.

  2015cites this paper
• Recent advances in pharmacotherapy for hypertriglyceridemia.

  2014cites this paper
• Lipid-Lowering and Antioxidant Functions of Bottle Gourd (Lagenaria siceraria) Extract in Human Dyslipidemia

  2014cites this paper
• Obesity Diabetes mellitus Oral estrogens ; selective estrogen receptor modulators Physical inactivity Polycystic ovary syndrome Beta-blockers Diet high in fat and simple sugars Hypothyroidism Thiazides Excessive alcohol consumption Nephrotic syndrome , chronic renal disease Atypical antipsychotics C

  2014influential citation
• Review article Postprandial lipemia as a cardiometabolic risk factor

  2014cites this paper
• Metabolic phenotypes of obesity influence triglyceride and inflammation homoeostasis

  2014cites this paper
• Postprandial lipemia as a cardiometabolic risk factor

  2014cites this paper
• Postprandial metabolism: from research to clinical practice

  2013cites this paper
• Postprandial Hypertriglyceridemia and Cardiovascular Disease: Current and Future Therapies

  2013cites this paper
• Postprandial dyslipidaemia and diabetes: mechanistic and therapeutic aspects

  2012cites this paper
• Evolution of Lipid Profiles after Bariatric Surgery

  2012cites this paper
• Fibrates and cardiorenal outcomes.

  2012cites this paper
• Hypertriglyceride Induced Acute Pancreatitis

  2012cites this paper
• Extended-release niacin acutely suppresses postprandial triglyceridemia.

  2012cites this paper
• Treatment of hypertriglyceridemia with fibric acid derivatives: impact on lipid subfractions and translation into a reduction in cardiovascular events.

  2011cites this paper
• Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement.

  2011cites this paper
• Options for the treatment of hyperlipidemia in Type 2 diabetes mellitus and hypothyroidism: lowering the cardiovascular risk.

  2011cites this paper
• Effects of oxidation on structural stability and remodeling of human very low density lipoprotein.

  2010cites this paper
• In vivo efficacy of acyl CoA: diacylglycerol acyltransferase (DGAT) 1 inhibition in rodent models of postprandial hyperlipidemia.

  2010cites this paper
• Relationship Between Adiponectin and Left Atrium Size in Uncomplicated Obese Patients: Adiponectin, a Link Between Fat and Heart

  2009cites this paper
• The effects of medications used for the management of dyslipidemia on postprandial lipemia.

  2009cites this paper
• Primary and secondary hypertriglyceridaemia.

  2009cites this paper
• Nonfasting Lipemia and Inflammation as Cardiovascular Disease Risks After SCI

  2009cites this paper
• The Ins and Outs of Adipose Tissue

  2009cites this paper